Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Karri Stark"'
Autor:
Julie L Boerner, Nicole Nechiporchik, Kelly L Mueller, Lisa Polin, Lance Heilbrun, Scott A Boerner, Gina L Zoratti, Karri Stark, Patricia M LoRusso, Angelika Burger
Publikováno v:
PLoS ONE, Vol 10, Iss 3, p e0119614 (2015)
Patients with metastatic triple-negative breast cancer (TNBC) have a poor prognosis. New approaches for the treatment of TNBC are needed to improve patient survival. The concept of synthetic lethality, brought about by inactivating complementary DNA
Externí odkaz:
https://doaj.org/article/4870bf194f7140bdb5a6912096e85e25
Publikováno v:
PLoS ONE, Vol 8, Iss 9, p e74525 (2013)
Aminoflavone (AF) acts as a ligand of the aryl hydrocarbon receptor (AhR). Expression of estrogen receptor α (ERα) and AhR-mediated transcriptional induction of CYP1A1 can sensitize breast cancer cells to AF. The objective of this study was to inve
Externí odkaz:
https://doaj.org/article/f1c2095de12143b69a502d9de9049640
Autor:
Anthony F. Shields, Joseph A. Fontana, Elisabeth I. Heath, Daryn W. Smith, Karri Stark, Julie Boerner, Kimberlee C. Dobson, Jawana M. Lawhorn-Crews, Lance K. Heilbrun, Izabela Podgorski, Ulka N. Vaishampayan
Purpose:Cabozantinib is a multitargeted tyrosine kinase inhibitor that demonstrated remarkable responses on bone scan in metastatic prostate cancer. Randomized trials failed to demonstrate statistically significant overall survival (OS). We studied t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ad5ac36e62fc75b4251d25ddeee8e8df
https://doi.org/10.1158/1078-0432.c.6529146
https://doi.org/10.1158/1078-0432.c.6529146
Autor:
Anthony F. Shields, Joseph A. Fontana, Elisabeth I. Heath, Daryn W. Smith, Karri Stark, Julie Boerner, Kimberlee C. Dobson, Jawana M. Lawhorn-Crews, Lance K. Heilbrun, Izabela Podgorski, Ulka N. Vaishampayan
Table S1. Baseline patient characteristics Table S2 Rank Correlations of Percent Change in Imaging with Percent Change in Bone Markers
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d3b7f9f2aa42f5c89a915b57a399520
https://doi.org/10.1158/1078-0432.22475685.v1
https://doi.org/10.1158/1078-0432.22475685.v1
Autor:
Patricia M. LoRusso, Michael E. Berens, Lance K. Heilbrun, Harshil D. Dhruv, Shwetal Mehta, Alanna Derogatis, Seongho Kim, Jianmei Wu, Karri Stark, Julie Boerner, Jing Li, Nader Sanai
Supplementary Figures and Tables
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3489e7cdd70286715b86a78203ebccb6
https://doi.org/10.1158/1078-0432.22475646.v1
https://doi.org/10.1158/1078-0432.22475646.v1
Supplementary Figure Legends from Phase 0 Trial of AZD1775 in First-Recurrence Glioblastoma Patients
Autor:
Patricia M. LoRusso, Michael E. Berens, Lance K. Heilbrun, Harshil D. Dhruv, Shwetal Mehta, Alanna Derogatis, Seongho Kim, Jianmei Wu, Karri Stark, Julie Boerner, Jing Li, Nader Sanai
Supplementary Figure Legends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52ff66c5ed059c664ab2c221134ce323
https://doi.org/10.1158/1078-0432.22475649
https://doi.org/10.1158/1078-0432.22475649
Autor:
Rouba Ali-Fehmi, Katrin Kiavash, Michele L. Cote, Gregory Dyson, Asra N. Shaik, Julie L. Boerner, Julie J. Ruterbusch, Karri Stark, Sudeshna Bandyopadhyay, Hany Deirawan
Publikováno v:
Breast cancer research and treatment. 185(3)
Markers of inflammation, including crown-like structures of the breast (CLS-B) and infiltrating lymphocytes (IL), have been identified in breast tissue and associated with increased risk of breast cancer (BrCa), however most of this work has been per
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e6445d24df0230f3da50112d656343f4
https://pubmed.ncbi.nlm.nih.gov/33113091
https://pubmed.ncbi.nlm.nih.gov/33113091
Autor:
Nader Sanai, Karri Stark, Julie L. Boerner, Michael E. Berens, Patricia LoRusso, Harshil Dhruv, Lance K. Heilbrun, Jing Li, Jianmei Wu, Alanna Derogatis, Shwetal Mehta, Seongho Kim
Publikováno v:
Clinical Cancer Research. 24:3820-3828
Purpose: AZD1775 is a first-in-class Wee1 inhibitor with dual function as a DNA damage sensitizer and cytotoxic agent. A phase I study of AZD1775 for solid tumors suggested activity against brain tumors, but a preclinical study indicated minimal bloo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::321ae9b261238ad2821fb0b3587b2a63
https://doi.org/10.1158/1078-0432.ccr-17-3348
https://doi.org/10.1158/1078-0432.ccr-17-3348
Autor:
Joseph A. Fontana, Ulka N. Vaishampayan, Julie L. Boerner, Elisabeth I. Heath, Lance K. Heilbrun, Karri Stark, Kimberlee Dobson, Daryn Smith, Jing Li, Manish K. Thakur
Publikováno v:
Clinical Genitourinary Cancer. 16:e695-e703
Background Pasireotide (SOM230; Novartis Inc, Basel, Switzerland) is a multitargeted somatostatin receptor analogue likely to treat the neuroendocrine, and docetaxel resistant components within metastatic castrate-resistant prostate cancer (mCRPC). T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c7b17d78bad0b3c35d41851ab728065
https://doi.org/10.1016/j.clgc.2018.01.019
https://doi.org/10.1016/j.clgc.2018.01.019
Autor:
Karri Stark, Lance K. Heilbrun, Jawana M. Lawhorn-Crews, Anthony F. Shields, Izabela Podgorski, Julie L. Boerner, Daryn Smith, Ulka N. Vaishampayan, Elisabeth I. Heath, Kimberlee Dobson, Joseph A. Fontana
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 25(2)
Purpose: Cabozantinib is a multitargeted tyrosine kinase inhibitor that demonstrated remarkable responses on bone scan in metastatic prostate cancer. Randomized trials failed to demonstrate statistically significant overall survival (OS). We studied
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d1eccaa608958dcd8981cd0d7ad1a11c
https://pubmed.ncbi.nlm.nih.gov/30327304
https://pubmed.ncbi.nlm.nih.gov/30327304